Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
Gain Therapeutics, Inc. (NASDAQ:GANX) announced Friday that it filed a prospectus supplement with the U.S. Securities and Exchange Commission for an “at the market offering” program. The filing allows the company to offer and sell up to $35,530,980.56 of its common stock, par value $0.0001 per share, from time to time through Oppenheimer & Co. Inc. as sales agent, under an existing Equity Distribution Agreement dated September 6, 2024.
According to the company’s statement in the SEC filing, as of Friday, Gain Therapeutics has already sold an aggregate of $14,469,019.44 of common stock through the distribution agreement and a related prospectus supplement dated September 6, 2024. The new prospectus supplement, dated Friday, and an accompanying base prospectus dated November 26, 2025, are part of the company’s shelf registration statement on Form S-3 (File No. 333-287622), which became effective November 26, 2025.
The company stated that Lowenstein Sandler LLP, its legal counsel, has issued a legal opinion regarding the validity of the shares that may be offered and sold under the program. The opinion is attached as an exhibit to the 8-K filing.
Gain Therapeutics’ common stock is listed on the NASDAQ Stock Market under the symbol GANX. The company noted that this report does not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction where such an offer or sale would be unlawful.
This information is based on a press release statement included in the company’s SEC filing.
In other recent news, Gain Therapeutics has shared preliminary results from its Phase 1b clinical study for its Parkinson’s drug, GT-02287. The company reported that the drug was safe and generally well tolerated after 90 days of treatment, with no serious adverse events observed. Some participants experienced temporary increases in liver enzymes, which normalized despite ongoing dosing. Additionally, interim data presented at the International Congress of Parkinson’s Disease and Movement Disorders showed improvements in MDS-UPDRS scores, a measure of Parkinson’s severity, among the first nine participants. Gain Therapeutics has also announced a nine-month extension to this study, with more than half of the 21 participants opting to continue their treatment. Approval from Australian ethics committees has allowed the dosing period to extend up to 12 months. Meanwhile, H.C. Wainwright has reiterated a Buy rating on Gain Therapeutics, maintaining an $8.00 price target. These recent developments provide a closer look at the progress of Gain Therapeutics’ experimental Parkinson’s treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.